SUDANESE JOURNAL OF PAEDIATRICS

2023; Vol 23, Issue No. 1

CASE REPORT

Acute hepatitis with non-alcoholic fatty liver disease-expanding clinical spectrum in COVID-19 exposed children: case report and review of literature

Sandeep Jhajra (1), Akshada Sharma (2), Kumar Diwakar (1), Bhupendra Kumar Gupta (1), Sanjay Kumar Tanti (1)

(1) Department of Paediatrics, Tata Main Hospital, Jamshedpur, India

(2) Department of Paediatrics, Post Graduate Institute of Medical Sciences, Rohtak, India

Correspondence to:

Bhupendra Kumar Gupta

Department of Paediatrics, Tata Main Hospital, Jamshedpur, India.

E mail: bhupendra.gupta [at] tatasteel.com

Received: 14 November 2021 | Accepted: 09 April 2022

How to cite this article:

Jhajra S, Sharma A, Diwakar K, Gupta BK, Tanti SK. Acute hepatitis with non-alcoholic fatty liver disease-expanding clinical spectrum in COVID-19 exposed children: case report and review of literature. Sudan J Paediatr. 2023;23(1): 91–97.

https://doi.org/10.24911/SJP.106-1636877693

ABSTRACT

Coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can adversely affect extra-pulmonary organs, such as the liver, heart and gastrointestinal tract apart from lungs. Although studies are showing that serum glutamic-oxaloacetic transaminase and serum glutamic-pyruvic transaminase are mildly elevated along with serum bilirubin in adult patients with mild to severe cases of COVID-19 disease, data are limited regarding liver injury in children infected with COVID virus. We report the case of a 9-year-old female patient who developed signs and symptoms of upper respiratory tract infection due to COVID-19 virus infection and subsequently developed fatty liver disease on follow-up. To our knowledge, this is the second case report in children showing an association between non-alcoholic fatty liver disease and SARS-CoV-2 virus infection.

---

Keywords:

Coronavirus; Liver injury; Non-alcoholic fatty liver disease.

---

INTRODUCTION

As of the 1st of November 2021 coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected more than 240 million people worldwide with more than 5 million deaths all over the world [1]. The first case of paediatric COVID-19 infection dates back to January 2020 wherein 10-year-old boy was infected in a family cluster of seven patients in China [2]. Most children infected with the coronavirus remain asymptomatic or have milder symptoms in the form of fever, cough, cold, nausea, vomiting, diarrhoea, abdominal pain and fatigue [3–6]. However, few children have hyperinflammatory responses 4–6 weeks after COVID infection also known as multi-system inflammatory syndrome [7,8].

Current evidence suggests that apart from lungs, the virus may also adversely affect extra-pulmonary organs, such as the liver, heart and gastrointestinal tract [9]. The SARS-CoV-2 virus can cause liver damage directly by binding of coronavirus to angiotensin-converting enzyme-2 (ACE-2) receptor in bile duct epithelial cells after translocation of virus from gut to liver or indirectly by other mechanisms like a systemic hyperinflammatory response, liver hypoxia and ischaemia [10–12]. Although studies are showing that serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamic-pyruvic transaminase (SGPT) are mildly elevated along with serum bilirubin in adult patients with mild to severe cases of COVID-19 disease [13], data is limited regarding liver injury in children infected with COVID virus, and the exact mechanism linking COVID-19 to paediatric fatty liver remains poorly understood due to its relatively asymptomatic course in paediatrics age group [12,14].

---

CASE REPORT

We report a case of a 9-year-old female with normal body mass index (BMI, weight was 33 kg with BMI of 19.5 kg/m²), who presented in our outpatient clinic with complaints of fatigue, loss of appetite and abdominal pain for 3–4 weeks. The patient had a history of an episode of upper respiratory tract infection in the form of fever, cough, cold and throat pain 6 weeks before present consultation, for which relevant investigations were taken. A nasopharyngeal swab for coronavirus real time-polymerase chain reaction for COVID-19 was positive. The patient had been advised of home isolation and symptomatic treatment with paracetamol. On further investigations, liver transaminases, SGOT and SGPT were raised, 344.2 and 401.7 U/l, respectively. C-reactive protein (CRP) was 2.13 mg/dl (normal range=0.08–1.12 mg/dl). Ultrasonography (USG) of the abdomen was normal. Laboratory parameters of the index case are shown in Table 1. The patient became afebrile after 72 hours and tested negative for COVID-19 after 2 weeks.

Table 1. Laboratory parameters of the index case.

Laboratory parameters	12/05/21	26/05/21	21/06/21	24/07/21
Hb (g/dl)	12.1	12.2	12.7
TLC (per cmm)	6,800	7,700	9,100
Neutrophils (%)	52	62	72
Lymphocytes (%)	42	29	22
Platelet count (per cmm)	225,000	276,000	329,000
CRP (g/dl)	2.13		0.9
Urine routine/micro	Normal
COVID-19	Target detected	Target not detected
Serum sodium (meq/l)	132		136
Serum potassium (meq/l)	4.5		5.2
SGOT(U/l)	344.2	249.4	190.4	17.7
SGPT (U/l)	401.7	324.5	210.6	17.4
Total/direct serum bilirubin (mg/dl)	3.28/1.1	1.92/0.14	0.46/0.11
ALP (U/l)		190.2	173.8	102
Serum albumin (g/dl)	4.0		3.8
PT/APTT		11/27.6	12.2/22.8
D-Dimer (ng FEU/ml)		760	510

ALP, Alkaline phosphatase; Hb, Haemoglobin; APTT, Activated partial thromboplastin time; Hb, Haemoglobin; PT, Prothrombin time; SGOT, Serum glutamic-oxaloacetic transaminase; SGPT, Serum glutamic-pyruvic transaminase; TLC, Total leukocyte count.

The patient presented in our outpatient clinic after 6 weeks of initial COVID illness with complaints of persistent fatigue, loss of appetite and abdominal pain. On clinical examination, she was conscious, alert and having normal blood pressure with a saturation of more than 95% in room air. Vitals including body temperature, heart rate and respiratory rate were normal with respect to age-matched controls. On auscultation chest was clear. The conjunctivae were clear without any redness or mucopurulent discharge. She did not have rash or petechiae over the body. The sclera was icteric. The cardiovascular examination was normal. There were no signs suggestive of clubbing, cyanosis or oedema. On abdominal examination, there was a dullness in the right hypochondrium region with non-tender hepatomegaly of 3 cm below the right costal margin with a smooth surface. Chest X-ray was unremarkable and 2D-echo suggestive of normal ejection fraction with no evidence of valvulitis.

Laboratory evaluation revealed decreasing levels of liver transaminases with SGOT of 190.4 U/l and SGPT of 210.6 U/l, respectively. Other markers of liver damage in the form of serum albumin, serum bilirubin, prothrombin time (PT) and aPTT were within normal limits (Table 1). Serum albumin was 3.8 (normal=3.5–5.6 g/dl) along with a random blood sugar of 83 mg/dl. Renal function tests and serum electrolytes came normal.

Further investigations performed for raised liver enzymes in the form of viral markers for hepatotropic viruses (hepatitis A, B, C and E), for leptospirosis and dengue were reported as normal. Workup for tuberculosis and typhoid was negative. Relevant investigations for cytokine storm, showed an erythrocyte sedimentation rate of 8 mm at the end of first hour and CRP of 0.9 mg/dl (normal=0.08–1.12 mg/dl) with serum ferritin, interleukin-6 and D Dimer values of 50 (normal=25–300 ng/ml), 5.4 pg/ml (normal=0.5–6.4 pg/ml) and 510 (normal=0–500 ng/ml), respectively. Serum lactate dehydrogenase level was 300 (normal=150–500 mg/dl). SARS-CoV-2 IgG antibody titre was <3.80 AU/ml (negative, reference value <12.0 AU/ml). USG of the abdomen was suggestive of increased liver span and increased hepatic echogenicity with the blurring of portal/hepatic vein suggestive of fatty liver disease (Figure 1). A thorough evaluation is needed to differentiate infective, metabolic and autoimmune causes of nonalcoholic fatty liver disease (NAFLD) in children, but due to gradual decline in liver enzymes and significant clinical improvement over the time workup for autoimmune causes, 24-hour urine copper or liver biopsy were not considered. Supportive therapy in the form of multivitamins and dietary advice was given. She was kept on follow-up. Liver enzymes came down to normal after 12 weeks with a reduction in liver size (Figure 2).

Figure 1. USG of abdomen showing increased liver span and increased hepatic echogenicity (arrow) with the blurring of portal/hepatic vein and obscured diaphragmatic outline (arrow).

Figure 2. Fall of liver transaminases over time in the index case. *SGOT, Serum glutamic-oxaloacetic transaminase; SGPT, Serum glutamic-pyruvic transaminase.

---

DISCUSSION

Children with COVID-19 infection have less severe symptoms and most of them present with milder manifestation in form of upper respiratory tract infection. In contrast to COVID-19 infection in adults, incidence of severe and fatal COVID-19 infection is less frequent in children. It is yet not well understood whether this age-related difference in severity is related to differential expression of ACE-2 receptor or lesser prevalence of co-morbidities or due to differential immune response to virus [13,15–17]. It has been postulated that cross-reactive antibodies due to repeated upper respiratory tract infections may confer protection against microbes with similar antigenic epitopes [17–19]. Furthermore, it has been postulated that Bacille Calmette-Guerin (BCG) vaccination may build up CD + 4 T helper 1 immunity, providing some protection against COVID-19 due to the cross-over immunity [20,21].

COVID-19-related liver injury is extrapulmonary manifestation of the disease and is characterised by variable degrees of liver damage due to the disease or its treatment in a patient with or without pre-existing liver disease [22]. Paediatric NAFLD is defined as hepatic steatosis in children aged ≤18 years in the absence of genetic diseases, metabolic disorders, infections like hepatitis C, use of steatogenic drugs, alcohol consumption or malnutrition [23]. Deranged liver enzymes are often observed in patients with COVID-19 usually in the form of elevated hepatic transaminases (SGPT and SGOT). Less frequently, mild elevations in gamma-glutamyl transferase, ALP and total bilirubin have also been reported. However, a significant impairment of liver function resulting in death in COVID-19 may occur rarely [24–27].

The aetiology of liver impairment is likely to be multifactorial, and includes direct liver damage by virus-induced cytopathic effect, immune-mediated inflammatory response, hypoxic injury associated with pneumonia and sepsis and liver injury caused by the use of hepatotoxic drugs [28,29]. In the index case liver enzymes were raised before the administration of paracetamol and therefore, we can completely exclude the possibility that any SGOT/SGPT abnormality caused by drug-induced injury.

Duan et al. [30] showed elevated serum levels of IL-1beta, IL-6, and IL-10 in COVID-19 patients with increased SGPT as compared to those patients with normal SGPT. However, Zhou et al. [31] showed no difference in levels of serum interleukins (IL-6 and IL-10) between COVID-19-infected children with and without elevated serum liver enzymes, indicating that interleukins may have questionable role in the pathogenesis of liver injury in COVID-19 paediatric patients]. Our index case has slightly elevated CRP (2.13 mg/dl), however, serum ferritin and serum interleukins were within normal limit. COVID-19-associated multisystem inflammatory conditions (MIS-C) which can present with liver and gastrointestinal involvement was ruled out in our case as our patient doesn’t meet the case definition of MIS-C given by World Health Organization [7,32,33].

Of interest, Cai et al. [34] study reported elevated transaminases at admission in COVID-19 children and adult patients due to the direct cytopathic effect of coronavirus infection on hepatocytes. A study from Italy shows an association between hepatic steatosis and SARS-CoV-2 infection in children [35]. In our case, the patient didn’t have underlying liver disease and liver impairment was found at first presentation of COVID-19 infection suggesting the possibility of direct cytopathic effect of coronavirus.

Due to the gradual decline in liver enzymes, significant clinical improvement over time and financial constraints workup for autoimmune causes, 24-hour urine copper or liver biopsy were not considered. Our patient presented with hepatitis with non-alcoholic fatty liver with mild respiratory symptoms adding to the spectrum of the illness that SARS-CoV-2 can present in children. The patient had a mild illness, did not have hypoxemia, pneumonia or cardiac dysfunction. Apart from SARS-CoV-2 infection, no other infectious aetiologies to explain persistent hepatitis and NAFLD were found.

---

CONCLUSION

This case report shows the spectrum of the presentation of COVID-19 infection in children and a unique association of coronavirus disease and fatty liver with hepatitis in children. Hepatic impairment can be observed in mild infection and patients with hepatitis should be investigated for COVID-19 infection during the pandemic time along with workup for other hepatotropic infections. NAFLD in COVID-19-exposed children warrant prolonged follow up. Further studies are required to determine the incidence and severity of hepatic involvement and to understand the underlying mechanism.

---

CONFLICT OF INTERESTS

The authors declare no conflict of interests.

---

FUNDING

None.

---

ETHICAL APPROVAL

Signed informed consent for participation and publication of medical details was obtained from the parents of this child. Confidentiality of patient’s data was ensured at all stages. The authors declare that ethics committee approval was not required for this case report.

---

REFERENCES

1. WHO Coronavirus Disease (COVID-19) Dashboard. World Health Organization; 2020 [cited 2020 June]. Available from: https://covid19.who.int/
2. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23. https://doi.org/10.1016/S0140-6736(20)30154-9
3. Mehta NS, Mytton OT, Mullins EWS, Fowler TA, Falconer CL, Murphy OB, et al. SARS-CoV-2 (COVID-19): what do we know about children? A systematic review. Clin Infect Dis. 2020;71(9):2469–79. https://doi.org/10.1093/cid/ciaa556
4. Parri N, Lenge M, Buonsenso D. Coronavirus infection in pediatric emergency departments (CONFIDENCE) research group. Children with COVID-19 in pediatric emergency departments in Italy. N Engl J Med. 2020;383(2):187–90. https://doi.org/10.1056/NEJMc2007617
5. CDC. COVID-19 response team. Coronavirus disease 2019 in children-United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):422–6. https://doi.org/10.15585/mmwr.mm6914e4
6. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3
7. Vogel TP, Top KA, Karatzios C, Hilmers DC, Tapia LI, Moceri P, et al. Multisystem inflammatory syndrome in children and adults (MIS-C/A): case definition & guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2021;39(22):3037–49. https://doi.org/10.1016/j.vaccine.2021.01.054
8. Feldstein LR, Rose EB, Randolph AG. Multisystem inflammatory syndrome in children in the United States-reply. N Engl J Med. 2020;383(18):1794–5. https://doi.org/10.1056/NEJMc2026136
9. Feng G, Zheng KI, Yan QQ, Rios RS, Targher G, Byrne CD, et al. COVID-19 and liver dysfunction: current insights and emergent therapeutic strategies. J Clin Transl Hepatol. 2020;8(1):18–24. https://doi.org/10.14218/JCTH.2020.00018
10. Hu LL, Wang WJ, Zhu QJ, Yang L. Novel coronavirus pneumonia-related liver injury: etiological analysis and treatment strategy. Zhonghua Gan Zang Bing Za Zhi. 2020;28(2):97.
11. Portincasa P, Krawczyk M, Smyk W, Lammert F, Di Ciaula A. COVID-19 and non-alcoholic fatty liver disease: two intersecting pandemics. Eur J Clin Invest. 2020;50(10):e13338. https://doi.org/10.1111/eci.13338
12. Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020;5(6):529–30. https://doi.org/10.1016/S2468-1253(20)30084-4
13. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
14. Di Sessa A, Lanzaro F, Zarrilli S, Picone V, Guarino S, Miraglia Del Giudice E, et al. COVID-19 and pediatric fatty liver disease: is there interplay? World J Gastroenterol. 2021;27(22):3064–72. https://doi.org/10.3748/wjg.v27.i22.3064
15. Kumar D, Michaels MG, Morris MI, Green M, Avery RK, Liu C, et al. American society of transplantation H1N1 collaborative study group. Outcomes from pandemic influenza a H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study. Lancet Infect Dis. 2010;10(8):521–6. https://doi.org/10.1016/S1473-3099(10)70133-X
16. Forster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci USA. 2020;117(17):9241–3. https://doi.org/10.1073/pnas.2004999117
17. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: why children fare better than adults? Indian J Pediatr. 2020;87(7):537–46. https://doi.org/10.1007/s12098-020-03322-y
18. Miri SM, Noorbakhsh F, Mohebbi SR, Ghaemi A. Higher prevalence of asymptomatic or mild COVID-19 in children, claims and clues. J Med Virol. 2020;92(11):2257–9. https://doi.org/10.1002/jmv.26069
19. Zhao LQ, Deng L, Cao L, Chen DM, Sun Y, Zhu RN, et al. Investigation of pathogenic agents causing acute respiratory tract infections in pediatric patients in a children’s hospital assigned for case screening in Beijing during the outbreak of COVID-19. Zhonghua Er Ke Za Zhi. 2020;58(8):635–9.
20. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc Natl Acad Sci USA. 2020;117(30):17720–6. https://doi.org/10.1073/pnas.2008410117
21. Redelman-Sidi G. Could BCG be used to protect against COVID-19? Nat Rev Urol. 2020;17(6):316–7. https://doi.org/10.1038/s41585-020-0325-9
22. Sun J, Aghemo A, Forner A, Valenti L. COVID-19 and liver disease. Liver Int. 2020;40(6):1278–81. https://doi.org/10.1111/liv.14470
23. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, Kohli R, et al. Naspghan clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the rxpert committee on NAFLD (ECON) and the North American society of pediatric gastroenterology, hepatology and nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr. 2017;64(2):319–4. https://doi.org/10.1097/MPG.0000000000001482
24. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. China medical treatment expert group for COVID-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–20. https://doi.org/10.1056/NEJMoa2002032
25. Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y, et al. Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study. J Hepatol. 2020;73(2):451–3. https://doi.org/10.1016/j.jhep.2020.03.044
26. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;69(6):1002–9. https://doi.org/10.1136/gutjnl-2020-320926
27. Haji Esmaeil Memar E, Mamishi S, Sharifzadeh Ekbatani M, Alimadadi H, Yaghmaei B, Chegini V, et al. Fulminant hepatic failure: a rare and devastating manifestation of coronavirus disease 2019 in an 11-year-old boy. Arch Pediatr. 2020;27(8):502. https://doi.org/10.1016/j.arcped.2020.09.009
28. Zhang C, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–30. https://doi.org/10.1016/S2468-1253(20)30057-1
29. Ahmed J, Rizwan T, Malik F, Akhter R, Malik M, Ahmad J, et al. COVID 19 and liver injury: a systematic review and meta analysis. Cureus. 2020;12(7):e9424. https://doi.org/10.7759/cureus.9424
30. Duan ZP, Chen Y, Zhang J, Zhao J, Lang ZW, Meng FK, et al. [Clinical characteristics and mechanism of liver injury in patients with severe acute respiratory syndrome]. Zhonghua Gan Zang Bing Za Zhi. 2003;11(8):493-6.
31. Zhou YH, Zheng KI, Targher G, Byrne CD, Zheng MH. Abnormal liver enzymes in children and infants with COVID-19: a narrative review of case-series studies. Pediatr Obes. 2020;15(12):e12723. https://doi.org/10.1111/ijpo.12723
32. Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, et al. Multisystem inflammatory syndrome related to COVID-19 in previously healthy children and adolescents in New York city. JAMA. 2020;324(3):294–6. https://doi.org/10.1001/jama.2020.10374
33. Cantor A, Miller J, Zachariah P, DaSilva B, Margolis K, Martinez M. Acute hepatitis is a prominent presentation of the multisystem inflammatory syndrome in children: a single-center report. Hepatology. 2020;72(5):1522–7. https://doi.org/10.1002/hep.31526
34. Cai Q, Huang D, Yu H, Zhu Z, Xia Z, Su Y, et al. COVID-19: abnormal liver function tests. J Hepatol. 2020;73(3):566–74. https://doi.org/10.1016/j.jhep.2020.04.006
35. Sica R, Pennoni S, Penta L, Di Cara G, Verrotti A. New onset of hepatic steatosis post-severe multisystem inflammatory syndrome in children (MIS-C): a case report. Int J Environ Res Public Health. 2021;18(13):6961. https://doi.org/10.3390/ijerph18136961